Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm

Introduction: Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associat...

Full description

Bibliographic Details
Authors: Formiga Pérez, Francesc, Chivite, David, Nuñez, Julio, Moreno García, Ma. Carmen, Manzano, Luis, Arévalo-Lorido, José Carlos, Cerqueiro, Jose Manuel, García Campos, Álvaro, Trullàs, Joan Carles, Montero Pérez-Barquero, Manuel
Format: article
Status:Published version
Publication Date:2022
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/190795
Online Access:https://hdl.handle.net/2445/190795
Access Level:Open access
Keyword:Angiotensines
Arrítmia
Mortalitat
Insuficiència cardíaca
Angiotensins
Arrhythmia
Mortality
Heart failure
id ES_eec069cfcf5f7639f4d2cbaede96beb0
oai_identifier_str oai:diposit.ub.edu:2445/190795
network_acronym_str ES
network_name_str España
repository_id_str
spelling Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythmFormiga Pérez, FrancescChivite, DavidNuñez, JulioMoreno García, Ma. CarmenManzano, LuisArévalo-Lorido, José CarlosCerqueiro, Jose ManuelGarcía Campos, ÁlvaroTrullàs, Joan CarlesMontero Pérez-Barquero, ManuelAngiotensinesArrítmiaMortalitatInsuficiència cardíacaAngiotensinsArrhythmiaMortalityHeart failureIntroduction: Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associated with the prescription of beta-blockers in patients discharged after an episode of HFpEF decompensation, and the clinical outcomes of these patients. Methods: We assessed 1078 patients with HFpEF and in sinus rhythm who had experienced an acute HF episode to explore whether prescription of beta-blockers on discharge was associated with one-year all-cause mortality or the composite endpoint of one-year all-cause death or HF readmission. We also examined the clinical factors associated with beta-blocker discharge prescription for such patients. Results: At discharge, 531 (49.3%) patients were on beta-blocker therapy. Patients on beta-blockers more often had a prior diagnosis of hypertension and more comorbidity (including ischemic heart disease) and a better functional status, but less often a prior diagnosis of chronic obstructive pulmonary disease. These patients had a lower heart rate on admission and more often used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and loop diuretics. One year after the index admission, 161 patients (15%) had died and 314 (29%) had experienced the composite endpoint. After multivariate adjustment, beta-blocker prescription was not associated with either all-cause mortality (HR=0.83 [95% CI 0.61-1.13]; p=0.236) or the composite endpoint (HR=0.98 [95% CI 0.79-1.23]; p=0.882). Conclusion: In patients with HFpEF in sinus rhythm, beta-blocker use was not related to one-year mortality or mortality plus HF readmission.Elsevier España2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/190795Articles publicats en revistes (Ciències Clíniques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.repc.2021.06.027Revista Portuguesa de Cardiologia, 2022, vol. 41, num. 10, p. 853-861https://doi.org/10.1016/j.repc.2021.06.027cc-by-nc-nd (c) Sociedade Portuguesa de Cardiologia , 2022https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1907952026-05-27T06:46:51Z
dc.title.none.fl_str_mv Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
title Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
spellingShingle Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
Formiga Pérez, Francesc
Angiotensines
Arrítmia
Mortalitat
Insuficiència cardíaca
Angiotensins
Arrhythmia
Mortality
Heart failure
title_short Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
title_full Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
title_fullStr Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
title_full_unstemmed Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
title_sort Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm
dc.creator.none.fl_str_mv Formiga Pérez, Francesc
Chivite, David
Nuñez, Julio
Moreno García, Ma. Carmen
Manzano, Luis
Arévalo-Lorido, José Carlos
Cerqueiro, Jose Manuel
García Campos, Álvaro
Trullàs, Joan Carles
Montero Pérez-Barquero, Manuel
author Formiga Pérez, Francesc
author_facet Formiga Pérez, Francesc
Chivite, David
Nuñez, Julio
Moreno García, Ma. Carmen
Manzano, Luis
Arévalo-Lorido, José Carlos
Cerqueiro, Jose Manuel
García Campos, Álvaro
Trullàs, Joan Carles
Montero Pérez-Barquero, Manuel
author_role author
author2 Chivite, David
Nuñez, Julio
Moreno García, Ma. Carmen
Manzano, Luis
Arévalo-Lorido, José Carlos
Cerqueiro, Jose Manuel
García Campos, Álvaro
Trullàs, Joan Carles
Montero Pérez-Barquero, Manuel
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Angiotensines
Arrítmia
Mortalitat
Insuficiència cardíaca
Angiotensins
Arrhythmia
Mortality
Heart failure
topic Angiotensines
Arrítmia
Mortalitat
Insuficiència cardíaca
Angiotensins
Arrhythmia
Mortality
Heart failure
description Introduction: Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associated with the prescription of beta-blockers in patients discharged after an episode of HFpEF decompensation, and the clinical outcomes of these patients. Methods: We assessed 1078 patients with HFpEF and in sinus rhythm who had experienced an acute HF episode to explore whether prescription of beta-blockers on discharge was associated with one-year all-cause mortality or the composite endpoint of one-year all-cause death or HF readmission. We also examined the clinical factors associated with beta-blocker discharge prescription for such patients. Results: At discharge, 531 (49.3%) patients were on beta-blocker therapy. Patients on beta-blockers more often had a prior diagnosis of hypertension and more comorbidity (including ischemic heart disease) and a better functional status, but less often a prior diagnosis of chronic obstructive pulmonary disease. These patients had a lower heart rate on admission and more often used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and loop diuretics. One year after the index admission, 161 patients (15%) had died and 314 (29%) had experienced the composite endpoint. After multivariate adjustment, beta-blocker prescription was not associated with either all-cause mortality (HR=0.83 [95% CI 0.61-1.13]; p=0.236) or the composite endpoint (HR=0.98 [95% CI 0.79-1.23]; p=0.882). Conclusion: In patients with HFpEF in sinus rhythm, beta-blocker use was not related to one-year mortality or mortality plus HF readmission.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/190795
url https://hdl.handle.net/2445/190795
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.repc.2021.06.027
Revista Portuguesa de Cardiologia, 2022, vol. 41, num. 10, p. 853-861
https://doi.org/10.1016/j.repc.2021.06.027
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Sociedade Portuguesa de Cardiologia , 2022
https://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Sociedade Portuguesa de Cardiologia , 2022
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier España
publisher.none.fl_str_mv Elsevier España
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423775083134976
score 15,300719

Similar Items